A 12‐gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5‐fluorouracil or FOLFIRI

Currently, there is no marker in use in the clinical management of colon cancer to predict which patients will respond efficiently to 5‐fluorouracil (5‐FU), a common component of all cytotoxic therapies. Our aim was to develop and validate a multigene signature associated with clinical outcome from...

Descripción completa

Detalles Bibliográficos
Autores principales: Paquet, Eric R., Cui, Jing, Davidson, David, Pietrosemoli, Natalia, Hassan, Houssein Hajj, Tsofack, Serges P., Maltais, Annie, Hallett, Michael T., Delorenzi, Mauro, Batist, Gerald, Aloyz, Raquel, Lebel, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939880/
https://www.ncbi.nlm.nih.gov/pubmed/27499901
http://dx.doi.org/10.1002/cjp2.17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939880/
https://www.ncbi.nlm.nih.gov/pubmed/27499901
http://dx.doi.org/10.1002/cjp2.17

Ejemplares similares